Research progress in drug repurposing in the treatment of breast cancer
TAN Chen,1, XU Zhangrun2, XUE Yang3, CHEN Jiayu4, YAO Lijun,5
1.Department of Orthopedics, Shanghai Sixth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
2.Laboratory of Molecular Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
3.Department of Clinical Laboratory, Shanghai Sixth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
4.Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China
5.Department of Endocrinology and Metabolism, Shanghai Sixth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
Breast cancer has become one of the most prevalent cancers among women worldwide, posing a significant burden on their health. Current standard therapies are often expensive and associated with the risk of drug resistance. Drug repurposing has gained increasing attention as a cost-effective and time-saving strategy in pharmaceutical research. Many drugs already in clinical use or undergoing clinical trials can be repurposed for the treatment of new clinical indications. Based on a comprehensive understanding of the mechanisms of action of these drugs and the pathophysiological processes of breast cancer, researchers can better identify drugs with potential anti-breast cancer properties and translate them into clinical practice. This paper provides a review of the current research on repurposing existing drugs for breast cancer treatment, summarizes the mechanisms of action of these drugs, and discusses the challenges associated with the strategy of drug repurposing.
Keywords：drug repurposing
;
breast cancer
;
chemotherapy
;
anti-tumor
TAN Chen, XU Zhangrun, XUE Yang, CHEN Jiayu, YAO Lijun. Research progress in drug repurposing in the treatment of breast cancer. Journal of Shanghai Jiao Tong University (Medical Science)[J], 2024, 44(11): 1454-1459 doi:10.3969/j.issn.1674-8115.2024.11.013
双硫仑的抗癌作用具有铜依赖性。其代谢产物二硫代氨基甲酸酯在肿瘤细胞中迅速累积并与铜形成络合物CuET，CuET可与核定位蛋白4（nuclear protein localization 4，NPL-4）结合并诱导其聚集，抑制p97-NPL4-UFD1途径，导致癌细胞内积累大量错误蛋白，最终导致癌细胞的凋亡［41］。双硫仑还可以作为乙醛脱氢酶1A1抑制剂发挥抗癌作用。乙醛脱氢酶1A1是包括乳腺癌在内的许多癌症的肿瘤起始细胞标志物，可诱导骨髓源性抑制细胞的增殖，导致免疫抑制，促进乳腺癌进展。因此，双硫仑联合骨髓源性抑制细胞耗竭剂吉西他滨能有效抑制TNBC细胞的生长［42］。鉴于双硫仑表现出的抗癌作用，其有望成为新的乳腺癌治疗药物。
TAN Chen and XU Zhangrun participated in the writing of the paper. XUE Yang and Chen Jiayu participated in the collection and collation of the literature. TAN Chen and YAO Lijun determined the topic selection and corrected the content of the review. All the authors have read the last version of paper and consented for submission.
利益冲突声明
所有作者声明不存在利益冲突。
COMPETING INTERESTS
All authors disclose no relevant conflict of interests.
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
REN J, WANG B, WU Q, et al. Combination of niclosamide and current therapies to overcome resistance for cancer: new frontiers for an old drug[J]. Biomed Pharmacother, 2022, 155: 113789.
GYAMFI J, LEE Y H, MIN B S, et al. Niclosamide reverses adipocyte induced epithelial-mesenchymal transition in breast cancer cells via suppression of the interleukin-6/STAT3 signalling axis[J]. Sci Rep, 2019, 9: 11336.
KIM J H, PARK S, JUNG E, et al. A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis[J]. Proc Natl Acad Sci USA, 2023, 120(21): e2304081120.
SANSONE P, STORCI G, TAVOLARI S, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland[J]. J Clin Invest, 2007, 117(12): 3988-4002.
ASGEIRSSON K S, OLAFSDÓTTIR K, JÓNASSON J G, et al. The effects of IL-6 on cell adhesion and e-cadherin expression in breast cancer[J]. Cytokine, 1998, 10(9): 720-728.
KORKAYA H, KIM G I, DAVIS A, et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population[J]. Mol Cell, 2012, 47(4): 570-584.
LIU H, YAN R, XIAO Z, et al. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling[J]. Breast Cancer Res, 2023, 25(1): 43.
TERRY M B, GAMMON M D, ZHANG F F, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk[J]. JAMA, 2004, 291(20): 2433-2440.
LØFLING L, STØER N C, NAFISI S, et al. Low-dose aspirin and risk of breast cancer: a Norwegian population-based cohort study of one million women[J]. Eur J Epidemiol, 2023, 38(4): 413-426.
BOWERS L W, MAXIMO I X, BRENNER A J, et al. NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions[J]. Cancer Res, 2014, 74(16): 4446-4457.
HAMY A S, TURY S, WANG X, et al. Celecoxib with neoadjuvant chemotherapy for breast cancer might worsen outcomes differentially by COX-2 expression and ER status: exploratory analysis of the REMAGUS02 trial[J]. J Clin Oncol, 2019, 37(8): 624-635.
LI C L, FANG Z X, WU Z, et al. Repurposed itraconazole for use in the treatment of malignancies as a promising therapeutic strategy[J]. Biomed Pharmacother, 2022, 154: 113616.
JIN M, ZENG B, LIU Y, et al. Co-delivery of repurposing itraconazole and VEGF siRNA by composite nanoparticulate system for collaborative anti-angiogenesis and anti-tumor efficacy against breast cancer[J]. Pharmaceutics, 2022, 14(7): 1369.
KHAN S, SHUKLA S, FARHAN M, et al. Centchroman prevents metastatic colonization of breast cancer cells and disrupts angiogenesis via inhibition of RAC1/PAK1/β-catenin signaling axis[J]. Life Sci, 2020, 256: 117976.
GÖBEL A, RAUNER M, HOFBAUER L C, et al. Cholesterol and beyond: the role of the mevalonate pathway in cancer biology[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(2): 188351.
BAI F, YU Z, GAO X, et al. Simvastatin induces breast cancer cell death through oxidative stress up-regulating miR-140-5p[J]. Aging (Albany NY), 2019, 11(10): 3198-3219.
YULIAN E D, SIREGAR N C, BAJUADJI. Combination of simvastatin and FAC improves response to neoadjuvant chemotherapy in locally advanced breast cancer[J]. Cancer Res Treat, 2021, 53(4): 1072-1083.
FELDT M, BJARNADOTTIR O, KIMBUNG S, et al. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial[J]. J Transl Med, 2015, 13: 133.
YU M, LI R, ZHANG J. Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer[J]. Biochem Biophys Res Commun, 2016, 471(4): 639-645.
JUNG M, LEE K M, IM Y, et al. Nicotinamide (niacin) supplement increases lipid metabolism and ROS-induced energy disruption in triple-negative breast cancer: potential for drug repositioning as an anti-tumor agent[J]. Mol Oncol, 2022, 16(9): 1795-1815.
AMARAL I, SILVA C, CORREIA-BRANCO A, et al. Effect of metformin on estrogen and progesterone receptor-positive (MCF-7) and triple-negative (MDA-MB-231) breast cancer cells[J]. Biomed Pharmacother, 2018, 102: 94-101.
MAHMOUDI G, EHTESHAMINIA Y, KOKHAEI P, et al. Enhancement of targeted therapy in combination with metformin on human breast cancer cell lines[J]. Cell Commun Signal, 2024, 22(1): 10.
ZANNELLA V E, DAL PRA A, MUADDI H, et al. Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response[J]. Clin Cancer Res, 2013, 19(24): 6741-6750.
MADAK J T, BANKHEAD A, CUTHBERTSON C R, et al. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer[J]. Pharmacol Ther, 2019, 195: 111-131.
BROWN K K, SPINELLI J B, ASARA J M, et al. Adaptive reprogramming of De novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer[J]. Cancer Discov, 2017, 7(4): 391-399.
LIU C, QIANG J, DENG Q, et al. ALDH1A1 activity in tumor-initiating cells remodels myeloid-derived suppressor cells to promote breast cancer progression[J]. Cancer Res, 2021, 81(23): 5919-5934.
ROBSON M, IM S A, SENKUS E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(6): 523-533.
LITTON J K, RUGO H S, ETTL J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation[J]. N Engl J Med, 2018, 379(8): 753-763.
XIA C, DONG X, LI H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.
